Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution

06 Nov 2016

• By Cathy Kelly

IV1610_USOutcomesContract_1200x675px

Related Content

Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza

21 Oct 2015

Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume

12 May 2016

Novartis To Payers: Entresto Works Or You Get A Discount

12 Feb 2016

Building A Foundation: Express Scripts’ Miller On Recent Outcomes-Based Contracts

29 Feb 2016

A Road Map To Strategic Drug Pricing

16 Mar 2016

Alzheimer’s Drugs and Medicare: A Case For Pre-Approval Discussions

21 Sep 2016

Merck/Aetna Pact Links Januvia Value-Based Payment To Treatment Intensification

11 Oct 2016

Lilly's Performance Contract For Trulicity Hinges On Head-To-Head Superiority

29 Jun 2016

Value-Based Contracting Needs Federal Safe Harbors To Flourish, Lilly Says

15 Jun 2016

Related Companies

Humana Inc.

Eli Lilly and Company

Anthem Inc.

Novartis AG

Amgen, Inc.

Merck & Co., Inc.

Express Scripts Holding Company

Cigna Corp.

Additional Topics

United States Market Access Reimbursement BioPharmaceutical

More from Market Access

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.